Актуальные вопросы патогенеза и терапии розацеа

Авторы:
  • Е. В. Свирщевская
    ФГБУН «Институт биоорганической химии им. М.М. Шемякина и Ю.В. Овчинникова» РАН, Москва, Россия, 117997
  • Е. В. Матушевская
    ФГБОУ ДПО «Институт повышения квалификации Федерального медико-биологического агентства России», Москва, Россия, 125371
  • Ю. И. Матушевская
    ГБУЗ МО «Люберецкий кожно-венерологический диспансер», Люберцы, Московская область, Россия, 140013
Журнал: Клиническая дерматология и венерология. 2017;16(4): 4-13
Просмотрено: 2306 Скачано: 665
Изучение вопросов патогенеза и лечения розацеа является актуальной проблемой современной дерматологии. Розацеа относится к акнеформным дерматозам, патогенез заболевания неясен. В данном обзоре приведены современные представления о патогенезе заболевания, классификация подтипов розацеа и подходы к терапии.
Ключевые слова:
  • розацеа
  • патогенез
  • классификация
  • терапия
  • метронидазол
  • Метрогил гель

КАК ЦИТИРОВАТЬ:

Свирщевская Е.В., Матушевская Е.В., Матушевская Ю.И. Актуальные вопросы патогенеза и терапии розацеа. Клиническая дерматология и венерология. 2017;16(4):4-13. https://doi.org/10.17116/klinderma20171644-13

Список литературы:

  1. Tan J, Schofer H, Araviiskaia E, Audibert F, Kerrouche N, Berg M. Prevalence of rosacea in the general population of Germany and Russia — the RISE study. J Eur Acad Dermatol Venereol. 2016;30:428-434. https://doi.org/10.1111/jdv.13556
  2. Wilkin J, Dahl M, Detmar M, Drake L, Feinstein A, Odom R, Powell F. Standard classification of rosacea: report of the national rosacea society expert committee on the classification and staging of rosacea. J Am Acad Dermatol. 2002 Apr;46(4):584-587.
  3. Федеральные клинические рекомендации по ведению больных розацеа. 2015. http://mzdrav.rk.gov.ru/file/Rozacea_05052014_Klinicheskie_rekomendacii.pdf
  4. Crawford GH, Pelle MT, James WD. Rosacea I: etiology, pathogenesis, and subtype classification. J Am Acad Dermatol. 2004;51:327-341.
  5. Tan J, Steinhoff M, Berg M, Del Rosso J, Layton A, Leyden J, Schauber J, Schaller M, Cribier B, Thiboutot D, Webster G; Rosacea International Study Group. Shortcomings in rosacea diagnosis and classification. Br J Dermatol. 2017 Jan;176(1):197-199. https://doi.org/10.1111/bjd.14819
  6. Spoendlin J, Voegel JJ, Jick SS, Meier CR. A study on the epidemiology of rosacea in the UK. Br J Dermatol. 2012;167.
  7. James Q. Del Rosso. Розацеа кожи: патогенез, клинические проявления, современные рекомендации по тактике ведения пациентов. Вестник дерматологии и венерологии 2016;(2):21-31.
  8. Chang AL, Raber I, Xu J, Li R, Spitale R, Chen J, Kiefer AK, Tian C, Eriksson NK, Hinds DA, Tung JY. Assessment of the genetic basis of rosacea by genome-wide association study. J Invest Dermatol. 2015 Jun;135(6): 1548-1555. https://doi.org/ 10.1038/jid.2015.53
  9. Aldrich N, Gerstenblith M, Fu P, Tuttle MS, Varma P, Gotow E, Cooper KD, Mann M, Popkin DL. Genetic vs environmental factors that correlate with rosacea: a cohort-based survey of twins. JAMA Dermatol. 2015 Nov; 151(11):1213-1219. https://doi.org/10.1001/jamadermatol.2015.2230
  10. Felton S, Navid F, Schwarz A, Schwarz T, Gläser R, Rhodes LE. Ultraviolet radiation-induced upregulation of antimicrobial proteins in health and disease. Photochem Photobiol Sci. 2013 Jan;12(1):29-36. https://doi.org/10.1039/c2pp25158b
  11. Bhat YJ, Manzoor S, Qayoom S. Steroid-induced rosacea: a clinical study of 200 patients. Indian J Dermatol. 2011 Jan;56(1):30-32. https://doi.org/10.4103/0019-5154.77547
  12. Niyonsaba F, Nagaoka I, Ogawa H, Okumura K. Multifunctional antimicrobial proteins and peptides: natural activators of immune systems. Curr Pharm Des. 2009;15(21):2393-2413.
  13. Sørensen OE, Thapa DR, Rosenthal A, Liu L, Roberts AA, Ganz T. Differential regulation of beta-defensin expression in human skin by microbial stimuli. J Immunol. 2005 Apr 15;174(8):4870-4879.
  14. Schibli DJ, Hunter HN, Aseyev V, Starner TD, Wiencek JM, McCray PB Jr, Tack BF, Vogel HJ. The solution structures of the human beta-defensins lead to a better understanding of the potent bactericidal activity of HBD3 against Staphylococcus aureus. J Biol Chem. 2002 Mar 8;277(10):8279-8289.
  15. K, Ogawa H. Antimicrobial peptides human beta-defensins stimulate epidermal keratinocyte migration, proliferation and production of proinflammatory cytokines and chemokines. J Invest Dermatol. 2007 Mar;127(3):594-604.
  16. Smithrithee R, Niyonsaba F, Kiatsurayanon C, Ushio H, Ikeda S, Okumura K, Ogawa H. Human β-defensin-3 increases the expression of interleukin-37 through CCR6 in human keratinocytes. J Dermatol Sci. 2015 Jan;77(1):46-53. https://doi.org/ 0.1016/j.jdermsci.2014.12.001
  17. Salzer S, Kresse S, Hirai Y, Koglin S, Reinholz M, Ruzicka T, Schauber J. Cathelicidin peptide LL-37 increases UVB-triggered inflammasome activation: possible implications for rosacea. J Dermatol Sci. 2014 Dec;76(3):173-179. https://doi.org/10.1016/j.jdermsci.2014.09.002
  18. Muto Y, Wang Z, Vanderberghe M, Two A, Gallo RL, Di Nardo A. Mast cells are key mediators of cathelicidin-initiated skin inflammation in rosacea. J Invest Dermatol. 2014 Nov;134(11):2728-2736. https://doi.org/10.1038/jid.2014.222
  19. Mishra S, Ahirwar DK, Ganju RK. Psoriasin (S100A7): a novel mediator of angiogenesis. Br J Dermatol. 2016 Dec;175(6):1141-1142. https://doi.org/ 10.1111/bjd.15141
  20. Rosenberg HF. RNase A ribonucleases and host defense: an evolving story. J Leukoc Biol. 2008 May;83(5):1079-1087. https://doi.org/10.1189/jlb.1107725
  21. Moali C, Hulmes DJ. Extracellular and cell surface proteases in wound healing: new players are still emerging. Eur J Dermatol. 2009 Nov-Dec;19(6):552-564. https://doi.org/10.1684/ejd.2009.0770
  22. Mangoni ML, McDermott AM, Zasloff M. Antimicrobial peptides and wound healing: biological and therapeutic considerations. Exp Dermatol. 2016 Mar;25(3):167-173. https://doi.org/ 10.1111/exd.12929
  23. Harder J, Bartels J, Christophers E, Schröder JM. A peptide antibiotic from human skin. Nature. 1997 Jun 26;387(6636):861.
  24. Bierkarre H, Harder J, Cuthbert R, Emery P, Leuschner I, Mrowietz U, Hedderich J, McGonagle D, Gläser R. Differential expression of antimicrobial peptides in psoriasis and psoriatic arthritis as a novel contributory mechanism for skin and joint disease heterogeneity. Scand J Rheumatol. 2016;45(3):188-196. https://doi.org/ 10.3109/03009742.2015.1091497
  25. Bracke S, Carretero M, Guerrero-Aspizua S, Desmet E, Illera N, Navarro M, Lambert J, Del Rio M. Targeted silencing of DEFB4 in a bioengineered skin-humanized mouse model for psoriasis: development of siRNA SECosome-based novel therapies. Exp Dermatol. 2014 Mar;23(3):199-201. https://doi.org/ 10.1111/exd.12321
  26. Nomura I, Goleva E, Howell MD, Hamid QA, Ong PY, Hall CF, Darst MA, Gao B, Boguniewicz M, Travers JB, Leung DY. Cytokine milieu of atopic dermatitis, as compared to psoriasis, skin prevents induction of innate immune response genes. J Immunol. 2003 Sep 15;171(6):3262-3269.
  27. Roediger B, Kyle R, Le Gros G, Weninger W. Dermal group 2 innate lymphoid cells in atopic dermatitis and allergy. Curr Opin Immunol. 2014 Dec;31:108-114. https://doi.org/ 10.1016/j.coi.2014.10.008
  28. Salimi M, Barlow JL, Saunders SP, Xue L, Gutowska-Owsiak D, Wang X, Huang LC, Johnson D, Scanlon ST, McKenzie AN, Fallon PG, Ogg GS. A role for IL-25 and IL-33-driven type-2 innate lymphoid cells in atopic dermatitis. J Exp Med. 2013 Dec 16;210(13):2939-2950. https://doi.org/ 10.1084/jem.20130351
  29. Rieg S, Steffen H, Seeber S, Humeny A, Kalbacher H, Dietz K, Garbe C, Schittek B. Deficiency of dermcidin-derived antimicrobial peptides in sweat of patients with atopic dermatitis correlates with an impaired innate defense of human skin in vivo. J Immunol. 2005 Jun 15;174(12):8003-8010.
  30. Harder J, Tsuruta D, Murakami M, Kurokawa I. What is the role of antimicrobial peptides (AMP) in acne vulgaris? Exp Dermatol. 2013 Jun;22(6):386-391. https://doi.org/ 10.1111/exd.12159
  31. Nakano T, Yoshino T, Fujimura T, Arai S, Mukuno A, Sato N, Katsuoka K. Reduced expression of dermcidin, a peptide active against propionibacterium acnes, in sweat of patients with acne vulgaris. Acta Derm Venereol. 2015 Sep;95(7):783-786. https://doi.org/ 10.2340/00015555-2068
  32. Lande R, Ganguly D, Facchinetti V, Frasca L, Conrad C, Gregorio J, Meller S, Chamilos G, Sebasigari R, Riccieri V, Bassett R, Amuro H, Fukuhara S, Ito T, Liu YJ, Gilliet M. Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus. Sci Transl Med. 2011 Mar 9;3(73):73ra19. https://doi.org/10.1126/scitranslmed.3001180
  33. Kreuter A, Hyun J, Skrygan M, Sommer A, Bastian A, Altmeyer P, Gambichler T. Ultraviolet A1-induced downregulation of human beta-defensins and interleukin-6 and interleukin-8 correlates with clinical improvement in localized scleroderma. Br J Dermatol. 2006 Sep;155(3):600-607.
  34. Schwab VD, Sulk M, Seeliger S, Nowak P, Aubert J, Mess C, Rivier M, Carlavan I, Rossio P, Metze D, Buddenkotte J, Cevikbas F, Voegel JJ, Steinhoff M. Neurovascular and neuroimmune aspects in the pathophysiology of rosacea. J Investig Dermatol Symp Proc. 2011 Dec;15(1):53-62. https://doi.org/10.1038/jidsymp.2011.6
  35. Yamasaki K, Di Nardo A, Bardan A, Murakami M, Ohtake T, Coda A, Dorschner RA, Bonnart C, Descargues P, Hovnanian A, Morhenn VB, Gallo RL. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat Med. 2007 Aug;13(8):975-980.
  36. Two AM, Del Rosso JQ. Kallikrein 5-mediated inflammation in rosacea: clinically relevant correlations with acute and chronic manifestations in rosacea and how individual treatments may provide therapeutic benefit. J Clin Aesthet Dermatol. 2014 Jan;7(1):20-25.
  37. Coda AB, Hata T, Miller J, Audish D, Kotol P, Two A, Shafiq F, Yamasaki K, Harper JC, Del Rosso JQ, Gallo RL. Cathelicidin, kallikrein 5, and serine protease activity is inhibited during treatment of rosacea with azelaic acid 15% gel. J Am Acad Dermatol. 2013 Oct;69(4):570-577. https://doi.org/ 10.1016/j.jaad.2013.05.019
  38. Bevins CL, Liu FT. Rosacea: Skin innate immunity gone awry? Nat. Med. 2007; 13:904-906. https://doi.org/ 10.1038/nm0807-904
  39. Muto Y, Wang Z, Vanderberghe M, Two A, Gallo RL, Di Nardo A. Mast cells are key mediators of cathelicidin-initiated skin inflammation in rosacea. J Invest Dermatol. 2014 Nov;134(11):2728-2736. https://doi.org/ 10.1038/jid.2014.222
  40. Ekiz O, Balta I, Sen BB, Dikilitaş MC, Ozuğuz P, Rifaioğlu EN. Vitamin D status in patients with rosacea. Cutan Ocul Toxicol. 2014 Mar;33(1):60-62. https://doi.org/10.3109/15569527.2013.797907
  41. Gombart A, Borregaard N, Koeffler H. Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1,25-dihydroxy vitamin D3. FASEB J. 2005;19(9);1067-1077. PubMed PMID: https://doi.org/10.1096/fj.04-3284com
  42. Liu P, Stenger S, Li H, Wenzel L, Tan B, Krutzik S, et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science. 206;311(5768):1770-1773. https://doi.org/10.1126/science.1123933
  43. Wang T, Nestel F, Bourdeau V, Nagai Y, Wang Q, Liao J, et al. Cutting edge: 1,25-dihydroxy vitamin D3 is a direct inducer of antimicrobial peptide gene expression J. Immunol. 2004;73(5):2909-2912.
  44. Wang TT, Dabbas B, Laperriere D, Bitton AJ, Soualhine H, Tavera-Mendoza LE, et al. Direct and indirect induction by 1,25-dihydroxy vitamin D3 of the NOD2/CARD15-defensin beta2 innate immune pathway defective in Crohn disease. J Biol Chem. 2010;285(4):2227-2231. https://doi.org/10.1074/jbc.C109.071225
  45. Melnik BC. Rosacea: The blessing of the celts — an approach to pathogenesis through translational research. Acta Derm Venereol. 2016 Feb;96(2):147-156. https://doi.org/10.2340/00015555-2220
  46. Egeberg A, Weinstock LB, Thyssen EP, Gislason GH, Thyssen JP. Rosacea and gastrointestinal disorders: a population-based cohort study. Br J Dermatol. 2017 Jan;176(1):100-106. https://doi.org/10.1111/bjd.14930
  47. Egeberg A, Hansen PR, Gislason GH, Thyssen JP. Clustering of autoimmune diseases in patients with rosacea. J Am Acad Dermatol. 2016 Apr;74(4):667-672.e1. https://doi.org/ 10.1016/j.jaad.2015.11.004
  48. 48.Spoendlin J, Karatas G, Furlano RI, Jick SS, Meier CR. Rosacea in patients with ulcerative colitis and crohn’s disease: a population-based case-control study. Inflamm Bowel Dis. 2016 Mar;22(3):680-687. https://doi.org/10.1097/MIB.0000000000000644
  49. Niyonsaba F, Kiatsurayanon C, Chieosilapatham P, Ogawa H. Friends or Foes? Host defense (antimicrobial) peptides and proteins in human skin diseases. Exp Dermatol. 2017 Feb 13. https://doi.org/10.1111/exd.13314
  50. Lee WJ, Jung JM, Lee YJ, Won CH, Chang SE, Choi JH, Moon KC, Lee MW. Histopathological analysis of 226 patients with rosacea according to rosacea subtype and severity. Am J Dermatopathol. 2016 May;38(5):347-352. https://doi.org/10.1097/DAD.0000000000000454
  51. Акбулатова Л.Х. Морфология двух форм клеща Demodex folliculorum hominis и его роль в заболеваниях кожи человека: Дис. … канд. мед. наук. Ташкент. 1968.
  52. Lacey N, Delaney S, Kavanagh K, et al. Mite related bacterial antigens stimulate inflammatory cells in rosacea. Br J Dermatol. 2007;157:474-481.
  53. Кубанов А.А., Галлямова Ю.А., Гревцева А.В. Роль клещей Demodex в развитии папуло-пустулезных дерматитов. Экспериментальная и клиническая дерматокосметология. 2014;2:43-46.
  54. Del Rosso JQ, Thiboutot D, Gallo R, et al. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 2: a status report on topical agents. Cutis. 2013;92:277-284.
  55. van Zuuren EJ, Fedorowicz Z, Carter B, van der Linden MM, Charland L. Interventions for rosacea. Cochrane Database Syst Rev. 2015 Apr 28;(4):CD003262. https://doi.org/ 10.1002/14651858.CD003262.pub5
  56. Millikan L. The proposed inflammatory pathophysiology of rosacea: implications for treatment. Skinmed. 2003 Jan-Feb;2(1):43-47.
  57. McMahon F, Banville N, Bergin DA, Smedman C, Paulie S, Reeves E, Kavanagh K. Activation of neutrophils via IP3 pathway following exposure to demodex-associated bacterial proteins. Inflammation. 2016 Feb;39(1): 425-433. https://doi.org/10.1007/s10753-015-0264-4
  58. O’Reilly N, Bergin D, Reeves EP, McElvaney NG, Kavanagh K. Demodex-associated bacterial proteins induce neutrophil activation. Br J Dermatol. 2012 Apr;166(4):753-760. https://doi.org/ 0.1111/j.1365-2133.2011.10746.x
  59. Narayanan S, Hünerbein A, Getie M, Jäckel A, Neubert RH. Scavenging properties of metronidazole on free oxygen radicals in a skin lipid model system. J Pharm Pharmacol. 2007 Aug;59(8):1125-1130.
  60. Jones D. Reactive oxygen species and rosacea. Cutis. 2004 Sep;74(3Suppl): 17-20, 32-34.
  61. Miyachi Y. Potential antioxidant mechanism of action for metronidazole: implications for rosacea management. Adv Ther. 2001 Nov-Dec;18(6): 237-243.
  62. Fararjeh M, Mohammad MK, Bustanji Y, Alkhatib H, Abdalla S. Evaluation of immunosuppression induced by metronidazole in Balb/c mice and human peripheral blood lymphocytes. Int Immunopharmacol. 2008 Feb; 8(2):341-350. https://doi.org/ 10.1016/j.intimp.2007.10.018
  63. Gutiérrez García M, López Lunar E, Fernández Arenas O, Hidalgo Correas FJ, García Díaz B. Farm Hosp. 2009 Jul-Aug;33(4):231-233.
  64. Park KI, Chung JM, Kim JY. Metronidazole neurotoxicity: sequential neuroaxis involvement. Neurol India. 2011 Jan-Feb;59(1):104-107. https://doi.org/10.4103/0028-3886.76882
  65. Del Rosso JQ. Azelaic Acid Topical Formulations: Differentiation of 15% Gel and 15% Foam. J Clin Aesthet Dermatol. 2017 Mar;10(3):37-40.
  66. Schulte BC, Wu W, Rosen T. Azelaic acid: evidence-based update on mechanism of action and clinical application. J Drugs Dermatol. 2015 Sep;14(9): 964-968.
  67. Ito T. Mazzotti reaction with eosinophilia after undergoing oral ivermectin for scabies. J Dermatol. 2013 Sep;40(9):776-777. https://doi.org/10.1111/1346-8138.12243
  68. Olson BG, Domachowske JB. Mazzotti reaction after presumptive treatment for schistosomiasis and strongyloidiasis in a Liberian refugee. Pediatr Infect Dis J. 2006 May;25(5):466-468.
  69. Катханова О.А., Катханов А.М., Стенин А.В. Комплексная терапия акнеформных дерматозов. Экспериментальная клиническая дерматокосметология. 2014;2:1-6.